Axsome Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Axsome Therapeutics (AXSM).

Price Target Range — 8 Quarters

Analyst Consensus — 20 Analysts

20Buy

Consensus RatingBuy# Analysts20Avg. Consensus PT$238Upside to Avg. PT+65.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 26, 2026	Piper Sandler	David Amsellem	PT Cut	Overweight	$258→$238
Oct 8, 2026	RBC Capital	Leonid Timashev	PT Cut	Outperform	$297→$295
Sep 29, 2026	Deutsche Bank	David Hoang	PT Cut	Buy	$280→$267
Sep 25, 2026	Morgan Stanley	Sean Laaman	PT Cut	Equal-Weight	$251→$247
Sep 23, 2026	Truist Securities	Srikripa Devarakonda	PT Raise	Buy	$200→$285
Sep 18, 2026	Piper Sandler	David Amsellem	Maintained	Overweight	$258
Aug 31, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$290
Aug 12, 2026	Mizuho	Graig Suvannavejh	PT Raise	Outperform	$306→$316
Aug 11, 2026	Morgan Stanley	Sean Laaman	PT Raise	Equal-Weight	$242→$251
Aug 11, 2026	RBC Capital	Leonid Timashev	PT Cut	Outperform	$304→$297
Aug 11, 2026	Guggenheim	Yatin Suneja	PT Raise	Buy	$260→$275
Aug 11, 2026	Wells Fargo	Benjamin Burnett	PT Raise	Overweight	$255→$256
Aug 11, 2026	Needham	Ami Fadia	PT Raise	Buy	$267→$268
Jul 31, 2026	Mizuho	Graig Suvannavejh	PT Cut	Outperform	$310→$306
Jul 21, 2026	BMO Capital	Malcolm Hoffman	Initiate	Outperform	$310
Jul 15, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$290
Jul 8, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$290
Jul 7, 2026	RBC Capital	Leonid Timashev	PT Raise	Outperform	$302→$304
Jun 17, 2026	TD Cowen	Joseph Thome	PT Raise	Buy	$275→$300
May 5, 2026	Morgan Stanley	Sean Laaman	PT Raise	Equal-Weight	$217→$242

Analyst Ratings News

PRO
Piper Sandler Maintains Overweight on Axsome Therapeutics, Lowers Price Target to $238

Piper Sandler analyst David Amsellem maintains Axsome Therapeutics (NASDAQ:AXSM) with a Overweight and lowers the price target from $258 to $238.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $295

RBC Capital analyst Leonid Timashev maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform and lowers the price target from $297 to $295.

Benzinga Newsdesk

PRO
Deutsche Bank Maintains Buy on Axsome Therapeutics, Lowers Price Target to $267

Deutsche Bank analyst David Hoang maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and lowers the price target from $280 to $267.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Equal-Weight on Axsome Therapeutics, Lowers Price Target to $247

Morgan Stanley analyst Sean Laaman maintains Axsome Therapeutics (NASDAQ:AXSM) with a Equal-Weight and lowers the price target from $251 to $247.

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Axsome Therapeutics, Raises Price Target to $285

Truist Securities analyst Srikripa Devarakonda maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and raises the price target from $200 to $285.

Benzinga Newsdesk

5 Stocks In The Spotlight Last Week: Wall Street's Most Accurate Analysts Weigh In

U.S. stocks ended mixed; the Dow had its worst week since March. Benzinga highlights top picks from five accurate analysts, including ON, AXSM and LLY.

Avi Kapoor

Axsome Therapeutics Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Axsome Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Piper Sandler Maintains Overweight on Axsome Therapeutics, Lowers Price Target to $238

PRO
RBC Capital Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $295

PRO
Deutsche Bank Maintains Buy on Axsome Therapeutics, Lowers Price Target to $267

PRO
Morgan Stanley Maintains Equal-Weight on Axsome Therapeutics, Lowers Price Target to $247

PRO
Truist Securities Maintains Buy on Axsome Therapeutics, Raises Price Target to $285

5 Stocks In The Spotlight Last Week: Wall Street's Most Accurate Analysts Weigh In

People Also Watch

People Also Watch

Axsome Therapeutics Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Axsome Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROPiper Sandler Maintains Overweight on Axsome Therapeutics, Lowers Price Target to $238

PRORBC Capital Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $295

PRODeutsche Bank Maintains Buy on Axsome Therapeutics, Lowers Price Target to $267

PROMorgan Stanley Maintains Equal-Weight on Axsome Therapeutics, Lowers Price Target to $247

PROTruist Securities Maintains Buy on Axsome Therapeutics, Raises Price Target to $285

5 Stocks In The Spotlight Last Week: Wall Street's Most Accurate Analysts Weigh In

People Also Watch

People Also Watch

PRO
Piper Sandler Maintains Overweight on Axsome Therapeutics, Lowers Price Target to $238

PRO
RBC Capital Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $295

PRO
Deutsche Bank Maintains Buy on Axsome Therapeutics, Lowers Price Target to $267

PRO
Morgan Stanley Maintains Equal-Weight on Axsome Therapeutics, Lowers Price Target to $247

PRO
Truist Securities Maintains Buy on Axsome Therapeutics, Raises Price Target to $285